INVESTIGATION OF THE MOLECULAR BASIS OF LENALIDOMIDE TREATMENT IN LYMPHOMA CELL LINES

INVESTIGATION OF THE MOLECULAR BASIS OF LENALIDOMIDE TREATMENT IN LYMPHOMA CELL LINES

Bibliographic Details
Main Authors:	Ballabio, E, Fernandez-Santamaria, C, Tramonti, D, Chen, X, Wainscoat, J, Boultwood, J, Hatton, C, Lawrie, C
Format:	Conference item
Published:	2010

Similar Items

Expression of microRNAs in diffuse large B cell lymphoma is associated with immunophenotype, survival and transformation from follicular lymphoma.
by: Lawrie, C, et al.
Published: (2009)

MicroRNA expression in chronic lymphocytic leukaemia.
by: Lawrie, C, et al.
Published: (2009)

MicroRNA expression in multiple myeloma is associated with genetic subtype, isotype and survival.
by: Chi, J, et al.
Published: (2011)

MicroRNA expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma.
by: Lawrie, C, et al.
Published: (2007)

MicroRNA expression in Sezary syndrome: identification, function, and diagnostic potential.
by: Ballabio, E, et al.
Published: (2010)

Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma.
by: Lawrie, C, et al.
Published: (2008)

Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression.
by: Jädersten, M, et al.
Published: (2009)

Expression profiling of persistent polyclonal B-cell lymphocytosis suggests constitutive expression of the AP-1 transcription complex and downregulation of Fas-apoptotic and TGFbeta signalling pathways.
by: Lawrie, C, et al.
Published: (2009)

The molecular basis of tick-host interactions
by: Lawrie, C, et al.
Published: (1999)

Lenalidomide selectively inhibits in vitro growth of the malignant clone in myelodysplastic syndrome (MDS) patients with 5q deletion.
by: Jadersten, M, et al.
Published: (2005)

Molecular pathogenesis of the myelodysplastic syndromes
by: Boultwood, J, et al.
Published: (1999)

Efficacy and safety of lenalidomide in the treatment of B-cell non-Hodgkin lymphoma
by: Yang Liu, et al.
Published: (2024-04-01)

P1103: INMIND: A PHASE 3 STUDY OF TAFASITAMAB PLUS LENALIDOMIDE AND RITUXIMAB VERSUS PLACEBO PLUS LENALIDOMIDE AND RITUXIMAB FOR RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL) OR MARGINAL ZONE LYMPHOMA (MZL)
by: L. H. Sehn, et al.
Published: (2022-06-01)

MicroRNA expression in multiple myeloma is associated with genetic subtype, isotype and survival
by: Pezzella Francesco, et al.
Published: (2011-05-01)

Carfilzomib-lenalidomide-dexamethasone in the management of lenalidomide-refractory multiple myeloma
by: C. Cerchione, et al.
Published: (2020-10-01)

P1219: ZANUBRUTINIB, LENALIDOMIDE PLUS R-CHOP (ZR2-CHOP) AS THE FIRST-LINE TREATMENT FOR NON-GCB DIFFUSED LARGE B-CELL LYMPHOMA (DLBCL)
by: H. Zhu, et al.
Published: (2022-06-01)

P1125: CELESTIMO: A PHASE III TRIAL EVALUATING THE EFFICACY AND SAFETY OF MOSUNETUZUMAB PLUS LENALIDOMIDE VERSUS RITUXIMAB PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
by: L. Nastoupil, et al.
Published: (2022-06-01)

Lenalidomide in Combination with Arsenic Trioxide: an Effective Therapy for Primary Effusion Lymphoma
by: Sara Moodad, et al.
Published: (2020-09-01)

Application of Lenalidomide on Diffused Large B-cell Lymphoma: Salvage, Maintenance, and Induction Treatment
by: Li-Yangxue Ma, et al.
Published: (2018-01-01)

Lenalidomide up-regulates SPARC and inhibits in vitro growth of the malignant clone in myelodysplastic syndrome patients with 5q deletion.
by: Pellagatti, A, et al.
Published: (2006)

PB2347: THE ROLE OF UPFRONT LENALIDOMIDE MAINTENANCE FOR PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA PATIENTS RESPONDING TO FIRST-LINE MTX TREATMENT
by: Yan Zhang, et al.
Published: (2023-08-01)

Comparison of Choi and Hans' algorithms by immunohistochemistry and quantitative reverse transcriptase-PCR - letter.
by: Ballabio, E, et al.
Published: (2010)

PB2266: TRIAL IN PROGRESS: PHASE 3 TRIAL OF ODRONEXTAMAB PLUS LENALIDOMIDE VERSUS RITUXIMAB PLUS LENALIDOMIDE IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND MARGINAL ZONE LYMPHOMA (OLYMPIA-5)
by: Umberto Vitolo, et al.
Published: (2023-08-01)

Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients.
by: Pellagatti, A, et al.
Published: (2007)

A rare case report of photosensitivity in non-hodgkin's lymphoma treated with lenalidomide
by: Rajesh K Soni, et al.
Published: (2020-01-01)

The Genetic and Molecular Basis for Canine Models of Human Leukemia and Lymphoma
by: Anne C. Avery
Published: (2020-01-01)

MicroRNA expression in lymphocyte development and malignancy.
by: Lawrie, C, et al.
Published: (2008)

MicroRNA expression in lymphocyte development and malignancy
by: Lawrie, C, et al.
Published: (2008)

Molecular characterization of the 7q deletion in myeloid disorders.
by: Lewis, S, et al.
Published: (1996)

Case Report: Successful Management of a Refractory Plasmablastic Lymphoma Patient With Tislelizumab and Lenalidomide
by: Lili Cheng, et al.
Published: (2021-07-01)

Lenalidomide treatment in relapsed/refractory B-cell lymphomas: A single center real-life experience
by: Mustafa Merter, et al.
Published: (2022-06-01)

NK cell activation and recovery of NK cell subsets in lymphoma patients after obinutuzumab and lenalidomide treatment
by: Dang-Nghiem Vo, et al.
Published: (2018-04-01)

Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma
by: Pieter Sonneveld, et al.
Published: (2022-10-01)

Identification and characterization of peripheral T-cell lymphoma-associated SEREX antigens.
by: Cooper, C, et al.
Published: (2011)

Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens
by: Cirino Botta, et al.
Published: (2021-04-01)

MOLECULAR MAPPING OF THE 7Q-DELETION IN MYELOID DISORDERS
by: Lewis, S, et al.
Published: (1993)

Detection of NPM-ALK DNA rearrangement in CD30 positive anaplastic large cell lymphoma.
by: Waggott, W, et al.
Published: (1995)

Lenalidomide for the treatment of relapsed and refractory multiple myeloma
by: van de Donk NW, et al.
Published: (2012-08-01)

The human POP2 gene: identification, sequencing, and mapping to the critical region of the 5q- syndrome.
by: Fidler, C, et al.
Published: (1999)

Telomere length in myelodysplastic syndromes.
by: Boultwood, J, et al.
Published: (1995)